Orexo AB (publ) (ORX.ST)

44.80 -1.65 (-3.55%) At close: 5:29PM CET

Orexo AB (publ)

Virdings allE 32 A
Uppsala 754 50
Sweden
46 1 87 80 88 00
http://www.orexo.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 138

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Nikolaj Sørensen	Pres & CEO	5.29M	N/A	1972
Mr. Joseph DeFeo	EVP & CFO	N/A	N/A	1961
Ms. Cecilia Coupland	VP & Head of Operations	N/A	N/A	1976
Lena Wange	Head of Investor Relations & Communications Director	N/A	N/A	N/A
Dr. Michael Sumner M.D.	Chief Medical Officer	N/A	N/A	1965
Mr. Johannes Doll	Exec. VP & Chief Commercial Officer	N/A	N/A	1981
Mr. Robert Rönn	VP and Head of R&D	N/A	N/A	1976
Mr. Dennis Urbaniak	Exec. VP of Digital Health	N/A	N/A	1969
Mr. Robert A. Deluca	Pres of Orexo US Inc	N/A	N/A	1961
Mr. Jesper Lind	Advisor	N/A	N/A	1960

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Orexo AB (publ), a specialty pharmaceutical company, and its subsidiaries develop and commercialize pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. The company's digital therapies comprise OXD01 for opioid use disorder and OXD02/vorvida for alcohol use disorder. Orexo AB (publ) has partnerships with Lyfebulb to recover from alcohol and opioid use disorders; and GoGoMeds to provide digital therapies deprexis and vorvida available for the treatment of depression and management of problematic alcohol misuse. The company was founded in 1995 and is headquartered in Uppsala, Sweden.

Corporate Governance

Orexo AB (publ)’s ISS Governance QualityScore as of December 2, 2020 is 7. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.